Teva Pharmaceutical Industries LTD Form 4 insider transactions
NYSE
Eric A. Hughes, an executive at Teva Pharmaceutical Industries, exercised restricted share units and sold a portion of the acquired shares to cover tax withholding obligations.
NYSE
EVP of International Markets at Teva Pharmaceutical Industries, Mark Sabag, reports acquisition and disposal of ordinary shares and restricted share units.
NYSE
Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the acquisition and disposal of ordinary shares and restricted share units.
NYSE
Form 4: Teva Pharmaceutical Industries: Chief Accounting Officer Amir Weiss Reports Share Transactions
Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the acquisition and disposal of ordinary shares and restricted share units.
NYSE
Form 4: Teva Pharmaceutical Industries: Acting Chief Legal Officer Dov Bergwerk Reports Share Transactions
Dov Bergwerk, Acting Chief Legal Officer of Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent ownership of ordinary shares.
NYSE
Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reported the disposal of 18,430 ordinary shares on February 28, 2024, following the vesting of restricted share units.
NYSE
Mark Sabag, EVP of International Markets at Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent ownership of ordinary shares.
NYSE
Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the disposal of 3,219 ordinary shares following the vesting of restricted share units on February 28, 2024.
NYSE
Executive VP of Global Operations at Teva Pharmaceutical Industries, Eric Drape, reports acquisition and disposal of ordinary shares to cover tax obligations related to vesting restricted share units.
NYSE
Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports the sale of 20,599 ordinary shares on February 28, 2024, along with the vesting of restricted share units.
NYSE
Vikki L. Conway, Acting Head of Global Human Resources at Teva Pharmaceutical Industries, sold 1,366 ordinary shares on February 28, 2024, to cover tax withholding obligations related to vesting restricted share units.